SCHEMBL7443335

SCHEMBL7443335

CCOC(=O)c1ncoc1CCNC(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
NCOR2 Q9Y618 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
TGM2 P21980 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
KEAP1 Q14145 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7429208 0.91 L3MBTL1 (0.52) MAPTL3MBTL1HDAC3HDAC4HDAC1
SCHEMBL7432590 0.88 HTT (0.53) MAPTL3MBTL1HDAC3HDAC4HDAC1
SCHEMBL7435982 0.87 MAPT (0.52) MAPTL3MBTL1HTTSMN1; SMN2LMNA
SCHEMBL22048857 0.85 LTA4H (0.49) MAPTL3MBTL1SMN1; SMN2LMNAALDH1A1
SCHEMBL21987950 0.83 MAPT (0.51) MAPTL3MBTL1HDAC3HDAC4HDAC1
SCHEMBL12203721 0.81 L3MBTL1 (0.49) MAPTL3MBTL1HTTLMNAALDH1A1
SCHEMBL21633575 0.81 MAPT (0.48) MAPTL3MBTL1HDAC3HDAC4HDAC1
SCHEMBL7433267 0.80 CTSL (0.54) TGM2
SCHEMBL12453030 0.80 NPSR1 (0.44) MAPTHTTALDH1A1ATM
SCHEMBL12138862 0.79 SMN1; SMN2 (0.45) MAPTSMN1; SMN2LMNAHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112424195-B Fused lactam derivatives 住友制药株式会社 2025-03-25 CN disclosed
US-20250084090-A1 SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY Sumitomo Pharma Co., Ltd. (JP) 2025-03-13 US disclosed
US-12180213-B2 Substituted pyrazoles showing serotonin 5-HT receptor activity SUMITOMO PHARMA CO. LTD. (JP) 2024-12-31 US disclosed
US-20230008875-A1 SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY Sumitomo Pharma Co., Ltd. (JP) 2023-01-12 US disclosed
US-11466007-B2 Substituted lactams showing serotonin 5-HT receptor activity Sumitomo Pharma Co., Ltd. (JP) 2022-10-11 US disclosed
EP-3828182-A1 FUSED RING LACTAM DERIVATIVES Sumitomo Dainippon Pharma Co., Ltd. (JP) 2021-06-02 EP disclosed
CN-112424195-A Condensed lactam derivatives 大日本住友制药株式会社 2021-02-26 CN disclosed
US-10745401-B2 Condensed lactam derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-18 US disclosed
US-20200255432-A1 CONDENSED LACTAM DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-13 US disclosed
US-20200172543-A1 CONDENSED LACTAM DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-06-04 US disclosed
US-8796300-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-08-05 US disclosed
US-8796300-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-08-05 US disclosed
US-20120238595-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-09-20 US disclosed
WO-2011057126-A1 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-05-12 WO disclosed
US-5312826-A Dicarboxylic acids with hypotensive agents and cardiovascular disorders TANABE SEIYAKU CO., LTD. (JP) 1994-05-17 US disclosed
EP-0519738-A1 Dicarboxylic acid derivatives and process for preparation thereof TANABE SEIYAKU CO., LTD. (JP) 1992-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255432-A1 CONDENSED LACTAM DERIVATIVE PSEN1, GRIN1, HDAC1 MAPT 38/4885L3MBTL1 4220/4885HDAC3 123/4885
US-20120238595-A1 THERAPEUTIC COMPOUNDS CCNY, MKI67, MCL1 MAPT 3240/4885L3MBTL1 1726/4885HDAC3 690/4885
US-20250084090-A1 SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY HTR1A, HTR5A, TPH1 MAPT 720/4885L3MBTL1 4601/4885HDAC3 2410/4885
US-12180213-B2 Substituted pyrazoles showing serotonin 5-HT receptor activity HTR5A, HTR1A, TPH1 MAPT 693/4885L3MBTL1 4786/4885HDAC3 596/4885
US-10745401-B2 Condensed lactam derivative PSEN1, GRIN1, HDAC1 MAPT 38/4885L3MBTL1 4220/4885HDAC3 123/4885
US-11466007-B2 Substituted lactams showing serotonin 5-HT receptor activity HTR1A, HTR5A, TPH1 MAPT 720/4885L3MBTL1 4601/4885HDAC3 2410/4885
US-20230008875-A1 SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY HTR1A, HTR5A, TPH1 MAPT 720/4885L3MBTL1 4601/4885HDAC3 2410/4885
US-20200172543-A1 CONDENSED LACTAM DERIVATIVE PSEN1, GRIN1, HDAC1 MAPT 38/4885L3MBTL1 4220/4885HDAC3 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.